Evozyne
Biotechnology ResearchIllinois, United States51-200 Employees
Evozyne designs novel protein therapeutics to solve previously unaddressable patient needs.
New CEO Evozyne recently appointed Marc Yoskowitz as the CEO, signaling potential changes in leadership direction and a chance for new partnerships or collaborations.
Generative AI Model Evozyne is developing a generative AI model in collaboration with NVIDIA, presenting an opportunity to leverage cutting-edge technology for enhancing product development and attracting tech-savvy clients.
Series B Financing With a recent $81M funding in Series B, Evozyne has financial resources to expand operations, invest in research, and potentially seek new clients or strategic acquisitions.
Protein Therapeutics Evozyne specializes in designing novel protein therapeutics, offering a unique value proposition that can attract pharmaceutical companies looking for innovative solutions for unaddressed patient needs.
Market Trends In an industry where AI-driven solutions and biotech advancements are gaining traction, Evozyne's focus on AI models and high-performing proteins aligns well with current market trends, presenting opportunities for partnerships with forward-thinking organizations.
Evozyne uses 8 technology products and services including GitHub, NoSQL, MySQL, and more. Explore Evozyne's tech stack below.
Evozyne Email Formats | Percentage |
First.Last@evozyne.com | 50% |
First.Last@evozyne.com | 50% |
Biotechnology ResearchIllinois, United States51-200 Employees
Evozyne designs novel protein therapeutics to solve previously unaddressable patient needs.
Evozyne has raised a total of $81M of funding over 3 rounds. Their latest funding round was raised on Sep 27, 2023 in the amount of $81M.
Evozyne's revenue is in the range of $10M$50M
Evozyne has raised a total of $81M of funding over 3 rounds. Their latest funding round was raised on Sep 27, 2023 in the amount of $81M.
Evozyne's revenue is in the range of $10M$50M